Cargando…

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

OBJECTIVE: To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sepúlveda, Maria, Armangué, Thaís, Sola-Valls, Nuria, Arrambide, Georgina, Meca-Lallana, José E., Oreja-Guevara, Celia, Mendibe, Mar, Alvarez de Arcaya, Amaya, Aladro, Yolanda, Casanova, Bonaventura, Olascoaga, Javier, Jiménez-Huete, Adolfo, Fernández-Fournier, Mireya, Ramió-Torrentà, Lluis, Cobo-Calvo, Alvaro, Viñals, Montserrat, de Andrés, Clara, Meca-Lallana, Virginia, Cervelló, Angeles, Calles, Carmen, Rubio, Manuel Barón, Ramo-Tello, Cristina, Caminero, Ana, Munteis, Elvira, Antigüedad, Alfredo R., Blanco, Yolanda, Villoslada, Pablo, Montalban, Xavier, Graus, Francesc, Saiz, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841645/ https://www.ncbi.nlm.nih.gov/pubmed/27144216 http://dx.doi.org/10.1212/NXI.0000000000000225

Ejemplares similares

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
por: Fernández, Óscar, et al.
Publicado: (2023)

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial
por: Villoslada, Pablo, et al.
Publicado: (2015)

Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5)
por: Meca-Lallana, Virginia, et al.
Publicado: (2019)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
por: Alonso Torres, A. M., et al.
Publicado: (2023)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
por: Lopez-Soley, Elisabet, et al.
Publicado: (2022)

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus
por: Sepulveda, Maria, et al.
Publicado: (2019)

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)

Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?
por: Arriaza, María José, et al.
Publicado: (2022)

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
por: Meca-Lallana, José E., et al.
Publicado: (2021)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
por: Meca-Lallana, Jose E, et al.
Publicado: (2021)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Information-Seeking Strategies of People with Multiple Sclerosis in Spain: The INFOSEEK-MS Study
por: Higueras, Yolanda, et al.
Publicado: (2022)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
por: Fernández-Velasco, José I., et al.
Publicado: (2022)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Cognitive impairment in multiple sclerosis: diagnosis and monitoring
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Tipografía y diseño : preimpresión digital de diarios
por: Lallana García, Fernando
Publicado: (2000)

SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry
por: Arrambide, Georgina, et al.
Publicado: (2021)

A Pilot Study to Explore Patient Satisfaction With a Virtual Rehabilitation Program in Multiple Sclerosis: The RehabVR Study Protocol
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Response to correspondence concerning “Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19”
por: Lallana, Sofia, et al.
Publicado: (2021)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection
por: Alvarez Bravo, G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nsd0jp183m77ccer908js65u6d